297 related articles for article (PubMed ID: 19325138)
1. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.
Mombelli G; Pazzucconi F; Bondioli A; Zanaboni A; Gaito S; Calabresi L; Sirtori CR
Cardiovasc Ther; 2010 Jun; 28(3):153-60. PubMed ID: 20337637
[TBL] [Abstract][Full Text] [Related]
4. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
5. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Wu TJ; Ou HY; Chou CW; Hsiao SH; Lin CY; Kao PC
Ann Clin Lab Sci; 2007; 37(2):158-66. PubMed ID: 17522372
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Magee G; Sharpe PC
J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
[TBL] [Abstract][Full Text] [Related]
7. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V
J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991
[TBL] [Abstract][Full Text] [Related]
8. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
10. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
[TBL] [Abstract][Full Text] [Related]
11. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H; Lefebvre B; Poulain P; Torra IP; Percevault F; Luc G; Peters JM; Gonzalez FJ; Gineste R; Helleboid S; Dzavik V; Fruchart JC; Fiévet C; Lefebvre P; Staels B
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
[TBL] [Abstract][Full Text] [Related]
12. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu J; Ye P
Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
16. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
Albert SG; Oiknine RF; Parseghian S; Mooradian AD; Haas MJ; McPherson T
Diabetes Care; 2007 Nov; 30(11):2800-3. PubMed ID: 17682119
[TBL] [Abstract][Full Text] [Related]
17. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Vergès B
Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]